We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-4.40 | -0.26% | 1,700.80 | 1,700.20 | 1,701.40 | 1,703.60 | 1,699.40 | 1,701.60 | 66,397 | 08:05:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.25 | 70.2B |
By Rory Gallivan
LONDON--The European Union has approved GlaxoSmithKline PLC's (GSK.LN) and Genmab A/S's (GEN.KO) leukemia treatment Arzerra to be used in patients unable to use an alternative drug.
The companies said Thursday that the EU has given marketing permission for Arzerra "as first-line treatment for chronic lymphocytic leukemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy."
Jan van de Winkel, chief executive of Genmab said: "This is another important milestone and we look forward to a successful launch under this new indication of the drug in Europe in the coming months."
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions